Stoke Therapeutics, Inc. (STOK) earnings
STOK earnings moved a median of +0.51% by the close. Quarterly and annual STOK reports and results, each read against the price at its own news timestamp. Back to the STOK overview →
21 measured STOK earnings events.
Where these STOK earnings landedvs 21 measured STOK earnings reactions
| Middle 50% of STOK earnings reactions | -3.29% to +4.01% |
|---|---|
| Median reaction (to close) | +0.51% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 STOK earnings events with a measured close landed between -3.29% and +4.01%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Stoke Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.45% | +10.04% | |
| Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates | Press release | +0.45% | +10.04% | |
| Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates | Press release | -1.03% | -0.94% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.52% | +3.04% | |
| Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates | Press release | +1.52% | +3.04% | |
| Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates | Press release | +2.20% | +0.88% | |
| Form 10-K Stoke Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.55% | -0.06% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -6.61% | +4.01% | |
| Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | -6.61% | +4.01% | |
| Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates | Press release | -8.93% | -4.88% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -8.80% | +13.57% | |
| Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | -8.80% | +13.57% | |
| Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates | Press release | -0.64% | +0.30% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.78% | +3.21% | |
| Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | -5.17% | -14.46% | |
| Form 10-K Stoke Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.79% | -7.71% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.68% | -3.29% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.35% | -0.70% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.68% | +0.51% | |
| Form 10-K Stoke Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +9.77% | -7.05% | |
| Form 10-Q Stoke Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.09% | -4.95% |
Keep exploring
More STOK: analyst actions → · SEC filings → · STOK overview →